Filing
1st Quarter - Report
Lobbying activity
7
Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launch
Section 232 investigation into pharmaceuticals and unfair trade practices
Sec. 232 investigation on pharmaceutical sector, tariffs, made in America
PBM reform, including spread pricing, AWP policy, ASP policy
PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty
BEAT, AMT, U.S. manufacturing incentives
Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP